<DOC>
	<DOCNO>NCT00380965</DOCNO>
	<brief_summary>This study design evaluate safety efficacy Cesamet™ control pain subject experience pain due chemotherapy-induced neuropathic pain patient cancer .</brief_summary>
	<brief_title>Evaluation Efficacy Cesamet™ Treatment Pain Patients With Chemotherapy-Induced Neuropathy</brief_title>
	<detailed_description>To determine safety efficacy Cesamet™ symptomatic treatment chemotherapy-induced neuropathic pain . This phase IV , multicenter , open label Cesamet™ 1 mg daily progress 2mg BID subject chemotherapy-induced neuropathic pain . This study two phase : A pretreatment phase treatment phase .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Nabilone</mesh_term>
	<criteria>Patients diagnose chemotherapyinduced neuropathic pain . Chronic daily pain present least 2 month . On stable analgesic regimen one month . Baseline pain score great 40mm VAS . Hypersensitivity compound study drug similar drug Pregnant lactate female Drug alcohol abuse Unstable medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Chemotherapy-induced</keyword>
	<keyword>neuropathy</keyword>
	<keyword>cancer</keyword>
</DOC>